Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
eltrombopag olamine
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Aevolode is a branded generic formulation of eltrombopag olamine, an orally active, small-molecule thrombopoietin receptor (TPO-R) agonist. Originally co-developed by Ligand Pharmaceuticals and GSK, and later transferred to Novartis, this generic version is marketed by Metrix Healthcare. Eltrombopag olamine interacts with the transmembrane domain of the human TPO receptor (c-Mpl), initiating intracellular signaling cascades via the JAK/STAT, AKT, and MAPK pathways. This stimulates the proliferation and differentiation of megakaryocytes from bone marrow progenitor cells, ultimately increasing platelet production. Aevolode is indicated for the treatment of thrombocytopenia in patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to other treatments, thrombocytopenia in patients with chronic hepatitis C to allow for interferon-based therapy, and severe aplastic anemia.
- Brand names
- AevolodeAevolode-25Aevolode25Aevolode 25Aevolode-50Aevolode50Aevolode 50
- Other names
- eltrombopag
02
Targets
BAKBAX (Apoptosis regulator BAX)TPOR (Thrombopoietin receptor)
Beyond the preview
Go deeper on eltrombopag olamine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on eltrombopag olamine.